Recombinant adenoviral vector and methods of use

Details Recombinant adenoviral vector and methods of use Recombinant adenoviral vector and methods of use

1997-10-28

1999-08-03

Guzo, David

Drug, bio-affecting and body treating compositions

Whole live micro-organism, cell, or virus containing

Genetically modified micro-organism, cell, or virus

424 936, 4353201, A61K 4800, C12N 1586

Patent

active

059322101

ABSTRACT:
This invention provides a recombinant adenovirus expression vector characterized by the partial or total deletion of the adenoviral protein IX DNA and having a gene encoding a foreign protein or a functional fragment or mutant thereof. Transformed host cells and a method of producing recombinant proteins and gene therapy also are included within the scope of this invention. Thus, for example, the adenoviral vector of this invention can contain a foreign gene for the expression of a protein effective in regulating the cell cycle, such as p53, Rb, or mitosin, or in inducing cell death, such as the conditional suicide gene thymidine kinase. (The latter must be used in conjunction with a thymidine kinase metabolite in order to be effective).

REFERENCES:
Bacchetti and Graham, "Inhibition of Cell Proliferation by an Adenovirus Vector Expressing the Human Wild Type p53 Protein"; Intl. J. of Oncology 3:781-788 (1993).
Bressac et al., "Abnormal Structure and Expression of p53 Gene in Human Hepatocellular Carcinoma"; Proc. Natl. Acad. Sci. USA 87:1973-1977 (1990).
Challberg and Kelly; Biochemistry 26:655-659 (1979).
Chen et al., "Genetic Mechanisms of Tumor Suppression by the Human p53 Gene"; Science 250:1576-1580 (1990).
Chen et al., "Expression of Wild-type p53 in Human A673 Cells Suppresses Tumorigenicity but Not Growth Rate"; Oncogene 6:1799-1805 (1991).
Cheng et al., "Suppression of Acute Lymphoblastic Leukemia by the Human Wild-Type p53 Gene"; Cancer Research 52:222-226 (1992).
El-Deiry et al., "WAF1, a Potential Mediator of p53 Tumor Suppression"; Cell 75:817-825 (1993).
Feinstein et al., "Expression of the Normal p53 Gene Induces Differentiation of K562 Cells", Oncogene 7:1853-1857 (1992).
Ghosh-Choudhury et al., "Protein IX, a Minor Component of the Human Adenovirus Capsid, is Essential for the Packaging of Full Length Genomes"; EMBO Journal 6:1733-1739 (1987).
Gooding and Wold, "Molecular Mechanisms by Which Adenoviruses Counteract Antiviral Immune Defenses" Crit. Rev. Immunol. 10:53-71 (1990).
Graham and Prevec, Vaccines: New Approaches to Immunological Problems R.W. Ellis (ed), Butterworth-Heinemann, Boston. pp. 363-390 (1992).
Heuvel et al., "Association between the Cellular p53 and the Adenovirus 5 E1B-55kd Proteins Reduces the Oncogenicity of Ad-transformed Cells"; EMBO Journal 9:2621-2629 (1990).
Hock et al., "Mechanisms of Rejection Induced by Tumor Cell-Targeted Gene Transfer of Interleukin 2, Interleukin 4, Interleukin 7, Tumor Necrosis Factor, or Interferon y"; Proc. Natl. Acad. Sci. USA 90:2774-2778 (1992).
Horowitz, M.S., "Adenoviridae and Their Replication"; In Fields Virology B.N. Fields, ed. (Raven Press, New York) pp. 1i679-1721 (1991).
Huang et al., "A Cellular Protein that Competes with SV40 T Antigen for Binding to the Retinoblastoma Gene Product"; Nature 350:160-162 (1991).
Hunter T., "Braking the Cycle"; Cell 75:839-841 (1993).
Jones and Shenk, "Isolation of Adenovirus Type 5 Host Range Deletion Mutants Defective for Transformation of Rat Embryo Cells"; Cell 17:683-689 (1979).
Kamb et al., "A Cell Cycle Regulator Potentially Involved in Genesis of Many Tumor Types"; Science 264:436-440 (1994).
Kuerbitz et al., "Wild-type p53 is a Cell Cycle Checkpoint Determinant Following Irradiation"; Proc. Natl. Acad. Sci. USA 89:7491-7495 (1992).
Lane, D.P., "p53, Guardian of the Genome"; Nature 358:15-16 (1992).
Lee et al., "Human Retinoblastoma Susceptibility Gene: Cloning, Identification, and Sequence"; Science 235:1394-1999 (1987).
Lemaistre et al., "Therapeutic Effects of Genetically Engineered Toxin (DAB.sub.486 IL-2) in Patient with Chronic Lymphocytic Leukaemia" Lancet 337:1124-1125 (1991).
Levine, A.J., "The Tumor Suppressor Genes"; Annu. Rev. Biochem. 62:623-651 (1993).
Lowe et al., "p53 is Required for Radiation-Induced Apoptosis in Mouse Thymocytes"; Nature 362:847-852 (1993).
Lowe et al., "p53-Dependent Apoptosis Modulates the Cytotoxicity of Anticancer Agents"; Cell 74:957-967 (1993).
Palmer et al., "Genetically Modified Skin Fibroblasts Persist Long After Transplantation but Gradually Inactive Introduced Genes"; Proc. Natl. Acad. Sci. USA 88:1330-1334 (1991).
Rao et al., "The Adenovirus E1A Proteins Induce Apoptosis, Which is Inhibited by the E1B 19-kDa and Bcl-2 Proteins"; Proc. Natl. Acad. Sci. USA 89:7742-7746 (1992).
Rosenfield et al., "In Vivo Transfer of the Human Cystic Fibrosis Transmembrane Conductance Regulator Gene to the Airway Epithelium"; Cell 68:143-155 (1992).
Sarnow et al., "Adenovirus E1b-58kd Tumor Antigen and SV40 Large Tumor Antigen are Physically Associated with the Same 54kd Cellular Protein in Transformed Cells"; Cell 28:387-394 (1982).
Siegfried W., "Perspectives in Gene Therapy with Recombinant Adenoviruses"; Exp. Clin. Endocrinol. 101:7-11 (1993).
Stewart et al., "Difference Imaging of Adenovirus: Bridging the Resolution Gap Between X-ray Crystallography and Electron Microscopy"; EMBO Journal 12(7):2589-2599 (1993).
Straus S.E., "Adenovirus Infections in Humans". In: The Adenoviruses, Ginsberg HS, ed. New York: Plenum Press, 451-496 (1984).
Takahashi et al., "Wild-type but not Mutant p53 Suppresses the Growth of Human Lung Cancer Cells Bearing Multiple Genetic Lesions"; Cancer Research 52:2340-2343 (1992).
Takahashi et al., "p53: A Frequent Target for Genetic Abnormalities in Lung Cancer"; Science 246:491-494 (1989).
Yonish-Rouach et al., "Wild-Type p53 Induces Apoptosis of Myeloid Leukaemic Cells that is Inhibited by Interleukin-6"; Nature 352:345-357 (1991).
Wang et al., "Quantitation of mRNA by the Polymerase Chain Reaction"; Proc. Natl. Acad. Sci. USA 86:9717-9721 (1989).
White et al., "The 19-Kilodalton Adenovirus E1B Transforming Protein Inhibits Programmed Cell Death and Prevents Cytolysis by Tumor Necrosis Factor .alpha."; Mol. Cell. Biol. 12:2570-2580 (1992).
R. Dijkema et al. Gene (1981) 13(4): 375-385.
J.A. Engler Gene (1981) 13(4): 387-394.
K. Zatloukal et al. Journal of Cellular Biochemistry (Mar. 17, 1993) SUP O, No. 17D, p. 129, Abstract NZ 522.
R. Gregory et al. Journal of Cellular Biochemistry (Jan. 15, 1994) SUP O, No. 18A, p. 237; Abstract DZ 307.
D.S. Shewach et al. Cancer Gene Therapy (1994) 1(2): 107-112.
L.K. Venkatesh et al. Proc. Natl. Acad. Sci. USA (Nov. 1990) 87: 8746-8750.
K.L. Berkner, Current Topics in Microbiology and Immunology, vol. 158, pp. 39-66, 1992.
Aiello et al., "Adenovirus 5 DNA Sequences Present and RNA Sequences Transcribed in Transformed Human Embryo Kidney Cells (HEK-Ad-5 or 293)," Virology 94:460-469 (1979).
Aulitzky et al., "Recombinant Tumour Necrosis Factor Alpha administered Subcutaneously or Intramuscularly for Treatmentof Advanced Malignant Disease: Phase I Trial," Eur. J. Cancer 27(4):462-467 (1991).
Austin et al., "A First Step in the Developement of Gene Therapy for Colorectal Carcinoma: Cloning, Sequencing, and Expression of Escherichia coli Cytosine Deaminase," Eur. J. Cancer 27(4):462-467 (1991).
Bacchetti et al., "Inhibition of cell proliferation by an adenovirus vector expressing the human wild type p53 protein," Int. J. Oncology 3:781-788 (1993).
Baker et al., "Suppression of Human Colrectal Carcinoma Cell Growth by Wild-Type p53," 249:912-915 (1990).
Bartek et al., "Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies," Oncogene 6:1699-1703 (1991).
Berkner et al., "Effect of the tripartite leader on synthesis of a non-viral protein in an adenovirus 5 recombinant," Nucleic Acids Research 13(3):841-857 (1985).
Boshart et al., "A Very Strong Enhancer is Located Upstream of an Immediate Early Gene of Human Cytomegalovirus," Cell 41:521-530 (1985).
Bressac et al., "Abnormal structure and expression of p53 gene in human hepatocellular carcinoma," Proc. Natl. Acad. Sci. U.S.A. 87:1973-1977 (1990).
Caruso et al., "Regression of established macroscopic liver metastatses after in situ transduction of a suicide gene," Proc. Natl. Acad. Sci. U.S.A. 90:7024-7028 (1993).
Casey et al., Oncogene 6(10):1791-1797 (1991).
Challberg et al., Proc. Natl. Acad. Sci. U.S.A. 76:655-659.
Chen et al., "Genetic Mechanisms of Tumor Supression

Affiliated with

Also associated with

Rating

Recombinant adenoviral vector and methods of use does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Recombinant adenoviral vector and methods of use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Recombinant adenoviral vector and methods of use will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-847397